Compare CLF & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLF | LQDA |
|---|---|---|
| Founded | 1847 | 2004 |
| Country | United States | United States |
| Employees | 25000 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.5B |
| IPO Year | 2006 | 2020 |
| Metric | CLF | LQDA |
|---|---|---|
| Price | $9.95 | $78.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $10.43 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 19.1M | 2.4M |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | N/A | ★ 0.52 |
| Revenue | ★ $18,610,000,000.00 | $158,320,000.00 |
| Revenue This Year | $8.76 | $278.87 |
| Revenue Next Year | $2.64 | $57.13 |
| P/E Ratio | ★ N/A | $147.92 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $7.36 | $11.85 |
| 52 Week High | $16.70 | $78.25 |
| Indicator | CLF | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 75.44 |
| Support Level | $8.82 | $31.23 |
| Resistance Level | $10.00 | N/A |
| Average True Range (ATR) | 0.72 | 4.14 |
| MACD | -0.47 | 0.40 |
| Stochastic Oscillator | 1.24 | 91.55 |
Cleveland-Cliffs Inc is a flat-rolled steel producer and manufacturer of iron ore pellets in North America. It is organized into four operating segments based on differentiated products, Steelmaking, Tubular, Tooling and Stamping and European Operations, but operates through one reportable segment -Steelmaking. It is vertically integrated from mined raw materials, direct reduced iron, and ferrous scrap to primary steelmaking and downstream finishing, stamping, tooling and tubing. It serves a diverse range of other markets due to its comprehensive offering of flat-rolled steel products. Geographically, it operates in the United States, Canada and other countries. The majority of revenue is from the United States. It is a supplier of steel to the automotive industry in North America.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.